Literature DB >> 26140278

PI3King the right partner: unique interactions and signaling by p110β.

Hashem A Dbouk1.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) are central regulators of cellular responses to extracellular stimuli, and are involved in growth, proliferation, migration, and metabolism. The Class I PI3Ks are activated by Receptor Tyrosine Kinases (RTKs) or G Protein-Coupled Receptors (GPCRs), and their signaling is commonly deregulated in disease conditions. Among the class I PI3Ks, the p110β isoform is unique in being activated by both RTKs and GPCRs, and its ability to bind Rho-GTPases and Rab5. Recent studies have characterized these p110β interacting partners, defining the binding mechanisms and regulation, and thus provide insight into the function of this kinase in physiology and disease. This review summarizes the developments in p110β research, focusing on the interacting partners and their role in p110β-mediated signaling.

Entities:  

Year:  2015        PMID: 26140278      PMCID: PMC4485402          DOI: 10.14304/surya.jpr.v3n6.8

Source DB:  PubMed          Journal:  Postdoc J        ISSN: 2328-9791


  118 in total

1.  Association of phosphatidylinositol 3-kinase composed of p110beta-catalytic and p85-regulatory subunits with the small GTPase Rab5.

Authors:  H Kurosu; T Katada
Journal:  J Biochem       Date:  2001-07       Impact factor: 3.387

2.  Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase.

Authors:  Lei Bi; Ichiro Okabe; David J Bernard; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2002-03       Impact factor: 2.957

Review 3.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

Review 4.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

5.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.

Authors:  J Yu; C Wjasow; J M Backer
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

Review 6.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

7.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Victor E Velculescu
Journal:  Cell Cycle       Date:  2004-10-12       Impact factor: 4.534

8.  Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.

Authors:  Inma M Berenjeno; Julie Guillermet-Guibert; Wayne Pearce; Alexander Gray; Stewart Fleming; Bart Vanhaesebroeck
Journal:  Biochem J       Date:  2012-02-15       Impact factor: 3.857

9.  Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).

Authors:  John E Burke; Roger L Williams
Journal:  Adv Biol Regul       Date:  2012-09-13

10.  Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs).

Authors:  Oscar Vadas; Hashem A Dbouk; Aliaksei Shymanets; Olga Perisic; John E Burke; Widian F Abi Saab; Bassem D Khalil; Christian Harteneck; Anne R Bresnick; Bernd Nürnberg; Jonathan M Backer; Roger L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

View more
  2 in total

1.  Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells.

Authors:  Daniel M Houslay; Karen E Anderson; Tamara Chessa; Suhasini Kulkarni; Ralph Fritsch; Julian Downward; Jonathan M Backer; Len R Stephens; Phillip T Hawkins
Journal:  Sci Signal       Date:  2016-08-16       Impact factor: 8.192

2.  ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.

Authors:  A M Simond; T Rao; D Zuo; J J Zhao; W J Muller
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.